Strategic Merger Pulmatrix has merged with Eos SENOLYTIX, signaling a strategy to expand pipeline and leverage combined resources for faster development and potential cross-selling of inhaled therapies.

iSPERSE Advantage The company’s proprietary iSPERSE delivery technology positions it to partner with pharma and contract manufacturers seeking optimized respiratory and non-respiratory drug delivery, enabling differentiated offerings.

Clinical Progress Active Phase II exploration for PUR3100 and prior Phase Ib data for PUR1800 indicate ongoing clinical development opportunities and potential near-term partnerships around inhaled NSKIs.

Financial Readiness With substantial funding and a recent private placement tied to the merger, Pulmatrix has capital flexibility to pursue collaborations, licensing deals, and accelerated clinical programs.

Global Reach Potential A focus on respiratory and non-respiratory therapies delivered via inhalation suggests partnerships across multiple therapeutic areas and markets, including COPD and other pulmonary or systemic conditions via inhaled routes.